Pipeline Collaboration Leverage Protalix's diverse pipeline including treatments for Fabry disease, respiratory diseases, severe gout, and NETs-related conditions to identify co-development or licensing opportunities with biotech firms seeking complementary modalities or expanded indications.

Plant Cell Advantage Position ProCellEx as a scalable, plant-based production platform offering potential cost, safety, and supply chain benefits to partners, suggesting collaboration with pharma seeking alternative manufacturing or rapid scale for rare disease biologics.

Strategic Partnerships Explore expansion of existing partnerships, notably with Chiesi Farmaceutici for elfabrio and Secarna for AI-driven candidate discovery, to create co-development deals, regional commercialization, or platform-enabled programs in new indications.

Financial Readiness Due to revenue range and ongoing funding, engage with Protalix on strategic financing, milestone-based collaborations, and potential equity financings to support pipeline advancement and commercial launches.

Executive Signals With leadership changes including a new CFO appointment, target conversations around financial planning, partner-led monetization strategies, and robust go-to-market plans to de-risk collaborations and accelerate value realization.